HC Wainwright reaffirmed their buy rating on shares of Vigil Neuroscience (NASDAQ:VIGL – Free Report) in a report published on Thursday, Benzinga reports. The firm currently has a $24.00 price objective on the stock.
Separately, Mizuho reduced their price objective on shares of Vigil Neuroscience from $15.00 to $13.00 in a research note on Thursday, August 10th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and an average price target of $18.40.
Vigil Neuroscience Stock Up 18.7 %
Vigil Neuroscience (NASDAQ:VIGL – Get Free Report) last announced its quarterly earnings data on Tuesday, August 8th. The company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.03. On average, equities analysts expect that Vigil Neuroscience will post -2.17 earnings per share for the current year.
Institutional Trading of Vigil Neuroscience
A number of large investors have recently made changes to their positions in the company. Bank of New York Mellon Corp bought a new stake in shares of Vigil Neuroscience in the first quarter worth about $94,000. Citigroup Inc. acquired a new position in shares of Vigil Neuroscience in the first quarter valued at approximately $451,000. BlackRock Inc. acquired a new position in shares of Vigil Neuroscience in the first quarter valued at approximately $2,135,000. Vanguard Group Inc. bought a new stake in shares of Vigil Neuroscience in the first quarter valued at about $2,708,000. Finally, Charles Schwab Investment Management Inc. bought a new stake in shares of Vigil Neuroscience in the first quarter valued at about $135,000. Institutional investors own 71.80% of the company’s stock.
Vigil Neuroscience Company Profile
Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101, a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.
- Five stocks we like better than Vigil Neuroscience
- High Dividend REITs: Are They an Ideal Way to Diversify?
- 5 Reasons Apple’s New Phone Moves the Needle: 5 That It Won’t
- The Significance of Brokerage Rankings in Stock Selection
- MarketBeat Week in Review – 9/11 – 9/15
- Large Cap Stock Definition and How to Invest
- China’s Jump In Car Sales Is Drawing Big Money To These Stocks
Receive News & Ratings for Vigil Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vigil Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.